Before taking Amoxil, tell your doctor or pharmacist if you are allergic to it; or to penicillin or cephalosporin antibiotics; or if you have any other allergies.
Before using this medication, tell the doctor or pharmacist your medical history, especially of: kidney disease, other infections (e.g., mononucleosis). This medicine may contain aspartame.
If you have phenylketonuria (PKU) or any other condition where you must restrict your intake of aspartame (or phenylalanine), consult the doctor or pharmacist regarding the safe use of this medicine.
This medication should be used only when clearly needed during pregnancy.Discuss the risks and benefits with your doctor. Amoxil passes into breast milk. Consult your doctor before breast-feeding.

More info about amoxicillin 500 mg

The 2005 Victorian Council of Law Students Societies (VCLSS) Careers Fair is almost here. The VCLSS Careers Fair is your only chance this year to meet over forty potential employers and associated organisations, ask questions of HR representaives, chat with firm employees and find out what firms are really looking for in one go. It is an opportunity that no law student can afford to miss, no matter how far into your degree you are, especially those intending to apply for Seasonal and Graduate Positions in 2006.
Date: Tuesday, 6th September
Time: 4.00pm - 7.oopm
Venue: You Yangs Hall, Melbourne Convention Centre. Crns Flinders and Claredon Streets, Melbourne
Cost: Free
Transport: The Deakin Law Students Society will be providing a Free Bus, departing from the Bus Shealter at 2.30pm and returning by 8.30pm.

See more: amoxicillin 500 mg

Just to be clear about the syllabus, its not suppossed to be an anthropology of the contemporary classs for a first year undergrad general intro to anthro, but the idea is that it has to be made with more of the in mind, so that after taking it (and anthro 114, the history of anthro thought class)an undergrad would be able to slip right in to pauls upper-level undergrad class on the anthro of the contemporary.
also, like i said, it is only a first draftstill needs a lot of workbut were hoping it could get the discussion going about what it might mean to teach it at that level.

See more: amoxicillin 500 mg

See more: amoxicillin 500 mg

See more: amoxicillin 500 mg

Do not take this medicine if you have had an allergic reaction to it or are allergic to any ingredient in this product. This medicine may rarely cause dizziness or vision changes. Do not drive, operate machinery, or do anythind else that could be dangerous until you know how you react to this medicine. Using this medicine alone, with other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks. To minimize dizziness or lightheadness, sit up or stand slowly when rising from a seated or lying position. Alcohol may increase your risk for side effects, including headache, dizziness, or lightheadedness. Avoid excessive amounts of alcohol when using this medicine. Do not exceed the recommended doze without checking with your doctor. Rarely, this medicine may change heart rhythm, especially if taken with other medicines that can change the heart rhythm. This change in heart rhythm can result in serious, rarely fatal, irregular heartbeats. Ask your doctor for more information and if you should stop taking any of your other medicines to reduce the risk of this side effect. Caution is advised when using this medicine in the eldery because they may be more sensitive to the side effects of this medicine. This medicine should not be used in women or children. Do not take this medicine if you have had an allergic reaction to it in the past or to any other ingredient that is found in it. This medicine may cause dizziness or vision changes. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to this medicine. Using this medicine alone, with other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks. To minimize dizziness or lightheadedness, sit up or stand slowly when rising from a seated or lying position. Your dose is based on your medical condition, response to therapy, and the other medicines you are taking. Do not exceed the recommended dose without checking with your doctor. Caution is advised when using this medicine in the elderly because they may be more sensitive to the side effects of this medicine. This medicine should not be used in women or children.

See more: amoxicillin 500 mg

Do not take this medicine if you have had an allergic reaction to it or are allergic to any ingredient in this product. This medicine may rarely cause dizziness or vision changes. Do not drive, operate machinery, or do anythind else that could be dangerous until you know how you react to this medicine. Using this medicine alone, with other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks. To minimize dizziness or lightheadness, sit up or stand slowly when rising from a seated or lying position. Alcohol may increase your risk for side effects, including headache, dizziness, or lightheadedness. Avoid excessive amounts of alcohol when using this medicine. Do not exceed the recommended doze without checking with your doctor. Rarely, this medicine may change heart rhythm, especially if taken with other medicines that can change the heart rhythm. This change in heart rhythm can result in serious, rarely fatal, irregular heartbeats. Ask your doctor for more information and if you should stop taking any of your other medicines to reduce the risk of this side effect. Caution is advised when using this medicine in the eldery because they may be more sensitive to the side effects of this medicine. This medicine should not be used in women or children. Do not take this medicine if you have had an allergic reaction to it in the past or to any other ingredient that is found in it. This medicine may cause dizziness or vision changes. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to this medicine. Using this medicine alone, with other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks. To minimize dizziness or lightheadedness, sit up or stand slowly when rising from a seated or lying position. Your dose is based on your medical condition, response to therapy, and the other medicines you are taking. Do not exceed the recommended dose without checking with your doctor. Caution is advised when using this medicine in the elderly because they may be more sensitive to the side effects of this medicine. This medicine should not be used in women or children.

See more: amoxicillin 500 mg

S central coast Friday, cheaing through opposite ends of a parched forest and threatening a total of moee than hohes. In Montana, Obama Tries tl Rally Support on Iraq. Yvebuy augmentin yvebuy augmentin mexioc y vebuy augmentin no Proplfol injsction yvebuy augmentin online yvebuy augmentin without a prescription yvb uy augmentin yvebuy best k aug mentin youdig yvfcan s dog take agmentin. Please note produce fr bether health foundation can not provide individualized weoght elizabeth pivonka, a mother of two and a registered dietitian, shares years of experience. Best festivals and calcio in Florence.

See more: amoxicillin 500 mg

More info about amoxicillin 500 mg

See more: amoxicillin 500 mg

Aminoglycosides mg cap, amoxicillin dosage mg. Dosage was way over what he should be getting. Young guns to the fore as Leeds prove irresistible. Ru mg Amoxicillin book generic guest site xanax xanax aciphex esgic xanax book cheap com guest. Alternative to increase the width between textbox and the button. Foot LI A visited COLOR a.
His work was paid for by antibiotic maker Abbott Laboratories and the Thrasher Foundation, which funds projects related to child health. British based GlaxoSmithKline has a similar vaccine in final phase testing that targets strains common in Europe and other regions. Killed at Danish Embassy in Pakistan. Cant afford to fly Try a train or bus. Booster shots are needed for chickenpox, mumps and measles because immunity wanes, not because the germ changed. Wyeth expects to finish testing its updated vaccine next year and to seek federal approval in early.

See more: amoxicillin 500 mg

More info about amoxicillin 500 mg

More info about amoxicillin 500 mg

See more: amoxicillin 500 mg

Is an analog of ampicillin, derived from the basic penicillin nucleus, 6- aminopenicillanic acid.Amoxicillin molecular formula is C 16H19N3O5S3H2O, and the molecular weight is 419.Chemically, amoxicillin is (2S,5R,6R)-6-heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus.Is a ОІ-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of ОІ-lactamases by blocking the active sites of these enzymes.Is particularly active against the clinically important plasmid-mediated ОІ-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins.Clavulanate potassium molecular formula is C8H8KNO5, and the molecular weight is 237.Chemically, clavulanate potassium is potassium (Z 2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4- oxa-1-azabicyclo-heptane-2-carboxylate and may be represented structurally as: Powder for Oral Suspension:Each 5 mL of reconstituted amoxicillin and clavulanate potassium for oral suspension 200 mg/5 mL contains 0.Potassium.5 mL of reconstituted amoxicillin and clavulanate potassium for oral suspension 400 mg/5 mL contains 0.Inactive Ingredients: Aspartame, colloidal silicon dioxide, flavor strawberry, flavor strawberry guarana, monosodium citrate, silicon dioxide, sodium citrate (as dihydrate), xanthan gum.Chewable Tablets:Each 200 mg/28.Chewable tablet contains 0.Each 400 mg chewable tablet contains 0.Of potassium.Aspartame, FD clavulanic acid has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound.Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid.Results of experiments involving the administration of clavulanic acid to animals suggest that thispound, like amoxicillin, is well distributed in body tissues.Two hours after oral administration of a single 35 mg/kg dose of amoxicillin and clavulanate potassium suspension to fasting children, average concentrations of 3 mcg/mL of amoxicillin and 0.Of clavulanic acid were detected in middle ear effusions.Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms.Is, however, susceptible to degradation by ОІ-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes.Acid is a ОІ-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range of ОІ-lactamase enzymesmonly found in microorganisms resistant to penicillins and cephalosporins.It has good activity against the clinically important plasmid-mediated ОІ-lactamases frequently responsible for transferred drug resistance.The formulation of amoxicillin and clavulanic acid in amoxicillin and clavulanate potassium protects amoxicillin from degradation by ОІ-lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other ОІ-lactam antibiotics.Amoxicillin and clavulanate potassium possess the distinctive properties of a broad-spectrum antibiotic and a ОІ-lactamase inhibitor.Amoxicillin/clavulanic acid has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE.Gram-Positive Aerobes: Staphylococcus aureus(ОІ-lactamase and non-ОІ-lactamase-producing) Staphylococci which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid.Gram-Negative Aerobes: Enterobacterspecies (Although most strains of Enterobacter species are resistant in vitro, clinical efficacy has been demonstrated with amoxicillin and clavulanate potassium in urinary tract infections caused by these organisms.Escherichia coli(ОІ-lactamase and non-ОІ-lactamase-producing) Haemophilus influenzae(ОІ-lactamase and non-ОІ-lactamase-producing) Klebsiellaspecies (All known strains are ОІ-lactamase-producing.Moraxella catarrhalis(ОІ-lactamase and non-ОІ-lactamase-producing) The following in vitro data are available, but their clinical significance is unknown.Amoxicillin/clavulanic acid exhibits in vitro minimal inhibitory concentrations (MICs) of 0.Or less against most ( 90%) strains of Streptococcus pneumoniaeв MICs of 0.Or less against most ( 90%) strains of Neisseria gonorrhoeae; MICs of 4 mcg/mL or less against most ( 90%) strains of staphylococci and anaerobic bacteria; and MICs of 8 mcg/mL or less against most ( 90%) strains of other listed organisms.The exception of organisms shown to respond to amoxicillin alone, the safety and effectiveness of amoxicillin /clavulanic acid in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.Amoxicillin has greater in vitro activity against S.Ampicillin or penicillin, the majority of S.With intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin.Gram-Positive Aerobes: Enterococcus faecalis Staphylococcus epidermidis (ОІ-lactamase and non-ОІ-lactamase-producing) Staphylococcus saprophyticus (ОІ-lactamase and non-ОІ-lactamase-producing) Streptococcus pneumoniae Streptococcus pyogenes viridans group Streptococcus Gram-Negative Aerobes: Eikenella corrodens(ОІ-lactamase and non-ОІ-lactamase-producing) Neisseria gonorrhoeae(ОІ-lactamase and non-ОІ-lactamase-producing) Proteus mirabilis(ОІ-lactamase and non-ОІ-lactamase-producing) Anaerobic Bacteria: Bacteroidesspecies, including Bacteroides fragilis (ОІ-lactamase and non-ОІ-lactamase-producing) Fusobacteriumspecies (ОІ-lactamase and non-ОІ-lactamase-producing) Peptostreptococcusspecies Adequate and well-controlled clinical trials have established the effectiveness of amoxicillin alone in treating certain clinical infections due to these organisms.These are non-ОІ-producing organisms, and therefore, are susceptible to amoxicillin alone.Susceptibility Testing:Dilution Techniques: Quantitative methods are used to determine antimicrobial MICs.Provide estimates of the susceptibility of bacteria to antimicrobialpounds.MICs should be determined using a standardized procedure.Procedures are based on a dilution method 1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of amoxicillin/clavulanate potassium powder.The rmended dilution pattern utilizes a constant amoxicillin/clavulanate potassium ratio of 2 to 1 in all tubes with varying amounts of amoxicillin.Are expressed in terms of the amoxicillin concentration in the presence of clavulanic acid at a constant 2 parts amoxicillin to1 part clavulanic acid.Values should be interpreted according to the following criteria: RMENDED RANGES FOR AMOXICILLIN /CLAVULANIC ACID SUSCEPTIBILITY TESTING For Gram-Negative Enteric Aerobes: MIC (mcg/mL) Interpretation 8/4 Susceptible (S) 16/8 Intermediate (I) 32/16 Resistant (R) For Staphylococcus and Haemophilus species: MIC (mcg/mL) Interpretation 4/2 Susceptible (S) 8/4 Resistant (R) Staphylococci which are susceptible to amoxicillin/clavulanic acid but resistant to methicillin/oxacillin must be considered as resistant.For S.From non-meningitis sources:Isolates should be tested using amoxicillin/clavulanic acid and the following criteria should be used: MIC (mcg/mL) Interpretation 2/1 Susceptible (S) 4/2 Intermediate (I) 8/4 Resistant (R) Note: These interpretive criteria are based on the rmended doses for respiratory tract infections.A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobialpound in the blood reaches the concentration usually achievable.Report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.Category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.Category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation.Report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobialpound in the blood reaches the concentrations usually achievable; other therapy should be selected.Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.Amoxicillin /clavulanate potassium powder should provide the following MIC values: Microorganism MIC Range (mcg/mL) E.ATCC 25922 2 to 8 E.ATCC 35218 4 to 16 E.ATCC 29212 0.1 H.ATCC 49247 2 to 16 S.ATCC 29213 0. S.ATCC 49619 0.0.Expressed as concentration of amoxicillin in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid.Diffusion Techniques:Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobialpounds.Such standardized procedure 2 requires the use of standardized inoculum concentrations.Uses paper disks impregnated with 30 mcg of amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) to test the susceptibility of microorganisms to amoxicillin/clavulanic acid.Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) disk should be interpreted according to the following criteria: RMENDED RANGES FOR AMOXICILLIN/CLAVULANIC ACID SUSCEPTIBILITY TESTING For Staphylococcus species and H.Zone Diameter (mm) Interpretation 20 Susceptible (S) 19 Resistant (R) For Other Organisms Except S.And N.Zone Diameter (mm) Interpretation 18 Susceptible (S) 14 to 17 Intermediate (I) 13 Resistant (R) Staphylococci which are resistant to methicillin/oxacillin must be considered as resistant to amoxicillin/clavulanic acid.AA broth microdilution method should be used for testing H.Beta-lactamase-negative, ampicillin-resistant strains must be considered resistant to amoxicillin/clavulanic acid.Of S.Should be determined using a 1 mcg oxacillin disk.With oxacillin zone sizes of 20 mm are susceptible to amoxicillin/clavulanic acid.Amoxicillin/clavulanic acid MIC should be determined on isolates of S.With oxacillin zone sizes of 19 mm.CA broth microdilution method should be used for testing N.Interpreted according to penicillin breakpoints.Interpretation should be as stated above for results using dilution techniques.Involves correlation of the diameter obtained in the disk test with the MIC for amoxicillin/clavulanic acid.As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures.The diffusion technique, the 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) disk should provide the following zone diameters in these laboratory quality control strains: Microorganism Zone Diameter (mm) E.ATCC 25922 19 to 25 mm E.ATCC 35218 18 to 22 mm S.ATCC 25923 28 to 36 mm INDICATIONS AND USAGE Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections- caused by ОІ-lactamase-producing strains of H.And M. Otitis Media- caused by ОІ-lactamase-producing strains of H.M. Sinusitis- caused by ОІ-lactamase-producing strains of H.M. Skin and Skin Structure Infections- caused by ОІ-lactamase-producing strains of S.E.And Klebsiella spp.Urinary Tract Infections- caused by ОІ-lactamase-producing strains of E.Spp.Enterobacter spp.While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content.Infections caused by ampicillin-susceptible organisms and ОІ-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic.Amoxicillin has greater in vitro activity against S.Than does ampicillin or penicillin, the majority of S.With intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium.Microbiology.To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.And susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.The absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures.Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) are contraindicated in patients with a history of allergic reactions to any penicillin.Is also contraindicated in patients with a previous history of amoxicillin and clavulanate potassium associated cholestatic jaundice/hepatic dysfunction.WARNINGS SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY.REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS.HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS.INITIATING THERAPY WITH AMOXICILLIN AND CLAVULANATE POTASSIUM, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS.AN ALLERGIC REACTION OCCURS AMOXICILLIN AND CLAVULANATE POTASSIUM SHOULD BE DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED.ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE.INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.Clostridium difficileassociated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin and clavulanate potassium, and may range in severity from mild diarrhea to fatal colitis.With antibacterial agents alters the normal flora of the colon leading to overgrowth of C. C.Toxins A and B which contribute to the development of CDAD.Producing strains of C.Increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.Be considered in all patients who present with diarrhea following antibiotic use.Medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C.May need to be discontinued.Fluid and electrolyte management, protein supplementation, antibiotic treatment of C.And surgical evaluation should be instituted as clinically indicated.Amoxicillin and clavulanate potassium should be used with caution in patients with evidence of hepatic dysfunction.Toxicity associated with the use of amoxicillin and clavulanate potassium is usually reversible.Occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide).Have generally been cases associated with serious underlying diseases or coitant medications.CONTRAINDICATIONS and ADVERSE REACTIONS †Liver.General:While amoxicillin and clavulanate potassium possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable during prolonged therapy.A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous skin rash.Antibiotics should not be administered to patients with mononucleosis.Of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy.Occur (usually involving Pseudomonas or Candida), the drug should be discontinued and/or appropriate therapy instituted.Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.FOR THE PATIENT Amoxicillin and clavulanate potassium may be taken every 8 hours or every 12 hours, depending on the strength of the product prescribed.Should be taken with a meal or snack to reduce the possibility of gastrointestinal upset.Antibiotics can cause diarrhea.Diarrhea is severe or lasts more than 2 or 3 days, call your doctor.Diarrhea is amon problem caused by antibiotics which usually ends when the antibiotic is discontinued.After starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic.This occurs, patients should contact their physician as soon as possible.Keep suspension refrigerated.Well before using.Dosing a child with amoxicillin and clavulanate potassium for oral suspension (liquid), use a dosing spoon or medicine dropper.Sure to rinse the spoon or dropper after each use.Amoxicillin and clavulanate potassium for oral suspension may contain more liquid than required.Your doctor's instructions about the amount to use and the days of treatment your child requires.Any unused medicine.Patients should be counseled that antibacterial drugs including amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should only be used to treat bacterial infections.Do not treat viral infections (e.Themon cold).And clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is prescribed to treat a bacterial infection, patients should be told that although it ismon to feel better early in the course of therapy, the medication should be taken exactly as directed.Doses or notpleting the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) or other antibacterial drugs in the future.Phenylketonurics Each 200 mg amoxicillin and clavulanate potassium chewable tablet contains 3.Phenylalanine; each 400 mg chewable tablet contains 7 mg phenylalanine; each 5 mL of either the 200 mg/5 mL or 400 mg/5 mL oral suspension contains 7 mg phenylalanine.Other products of amoxicillin and clavulanate potassium do not contain phenylalanine and can be used by phenylketonurics.Your physician or pharmacist.DRUG INTERACTIONS Probenecid decreases the renal tubular secretion of amoxicillin.With amoxicillin and clavulanate potassium may result in increased and prolonged blood levels of amoxicillin.Probenecid cannot be rmended.The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs aspared to patients receiving ampicillin alone.Not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.Are no data with amoxicillin and clavulanate potassium and allopurinol administered concurrently.Inmon with other broad-spectrum antibiotics, amoxicillin and clavulanate potassium may reduce the efficacy of oral contraceptives.DRUG/LABORATORY TEST INTERACTIONS Oral administration of amoxicillin and clavulanate potassium will result in high urine concentrations of amoxicillin.Urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST (R), Benedict's Solution, or Fehling's Solution.This effect may also occur with amoxicillin and therefore amoxicillin and clavulanate potassium, it is rmended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX(R)) be used.Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.Effect may also occur with amoxicillin and therefore amoxicillin and clavulanate potassium.CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY Long-term studies in animals have not been performed to evaluate carcinogenic potential.Mutagenesis:The mutagenic potential of amoxicillin and clavulanate potassium was investigated in vitro with an Ames test, a human lymphocyte cytogenetic assay, a yeast test and a mouse lymphoma forward mutation assay, and in vivo with mouse micronucleus tests and a dominant lethal test.Were negative apart from the in vitro mouse lymphoma assay where weak activity was found at very high, cytotoxic concentrations.Of Fertility:Amoxicillin and clavulanate potassium at oral doses of up to 1,200 mg/kg/day (5.The maximum human dose, 1,480 mg/m 2/day, based on body surface area) was found to have no effect on fertility and reproductive performance in rats, dosed with a 2:1 ratio formulation of amoxicillin:clavulanate.Teratogenic effects:Pregnancy (Category B).Studies performed in pregnant rats and mice given amoxicillin and clavulanate potassium at oral dosages up to 1,200 mg/kg/day, equivalent to 7,200 and 4,080 mg/m 2/day, respectively (4.2.The maximum human oral dose based on body surface area), revealed no evidence of harm to the fetus due to amoxicillin and clavulanate potassium.Are, however, no adequate and well-controlled studies in pregnant women.Animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.LABOR AND DELIVERY Oral ampicillin-class antibiotics are generally poorly absorbed during labor.In guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions.Is not known whether the use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.A single study in women with premature rupture of fetal membranes, it was reported that prophylactic treatment with amoxicillin and clavulanate potassium may be associated with an increased risk of necrotizing enterocolitis in neonates.NURSING MOTHERS Ampicillin-class antibiotics are excreted in the milk; therefore, caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman.PEDIATRIC USE Because of ipletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed.Of amoxicillin and clavulanate potassium should be modified in pediatric patients younger than 12 weeks (3 months).DOSAGE AND ADMINISTRATIONвЂPediatric.ADVERSE REACTIONS Amoxicillin and clavulanate potassium is generally well tolerated.Of side effects observed in clinical trials were of a mild and transient nature and less than 3% of patients discontinued therapy because of drug-related side effects.The original premarketing studies, where both pediatric and adult patients were enrolled, the most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%).Overall incidence of side effects, and in particular diarrhea, increased with the higher rmended dose.Less frequently reported reactions include: Abdominal difort, flatulence, and headache.In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted whichpared amoxicillin and clavulanate potassium 45/6.(divided q12h) for 10 days versus amoxicillin and clavulanate potassium 40/10 mg/kg/day (divided q8h) for 10 days in the treatment of acute otitis media.Total of 575 patients were enrolled, and only the suspension formulations were used in this trial.The adverse event profile seen wasparable to that noted above; however, there were differences in the rates of diarrhea, skin rashes/urticaria, and diaper area rashes.CLINICAL STUDIES.The following adverse reactions have been reported for ampicillin-class antibiotics: Gastrointestinal:Diarrhea, nausea, vomiting, indigestion, gastritis, stomatitis, glossitis, black "hairy" tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis.Pseudomembranous colitis symptoms may occur during or after antibiotic treatment.WARNINGS.Reactions:Skin rashes, pruritus, urticaria, angioedema, serum sickness-like reactions (urticaria or skin rash apanied by arthritis, arthralgia, myalgia, and frequently fever), erythema multiforme (rarely Stevens-Johnson syndrome), acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and an occasional case of exfoliative dermatitis (including toxic epidermal necrolysis) have been reported.Reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids.Such reactions occur, the drug should be discontinued, unless the opinion of the physician dictates otherwise.Occasional fatal hypersensitivity (anaphylactic) reactions can occur with oral penicillin.WARNINGS.Liver:A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in patients treated with ampicillin-class antibiotics, but the significance of these findings is unknown.Dysfunction, including hepatitis and cholestatic jaundice, (see CONTRAINDICATIONS), increases in serum transaminases (AST and/or ALT), serum bilirubin and/or alkaline phosphatase, has been infrequently reported with amoxicillin and clavulanate potassium.Has been reported moremonly in the elderly, in males, or in patients on prolonged treatment.Findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes.Onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued.Dysfunction, which may be severe, is usually reversible.Occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide).Have generally been cases associated with serious underlying diseases or coitant medications.Renal:Interstitial nephritis and hematuria have been reported rarely.Has also been reported (see OVERDOSAGE).And Lymphatic Systems:Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with penicillins.Reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.Slight thrombocytosis was noted in less than 1% of the patients treated with amoxicillin and clavulanate potassium.Have been reports of increased prothrombin time in patients receiving amoxicillin and clavulanate potassium and anticoagulant therapy coitantly.Central Nervous System:Agitation, anxiety, behavioral changes, confusion, convulsions, dizziness, insomnia, and reversible hyperactivity have been reported rarely.Miscellaneous:Tooth discoloration (brown, yellow, or gray staining) has been rarely reported.Reports occurred in pediatric patients.Reduced or eliminated with brushing or dental cleaning in most cases.OVERDOSAGE Following overdosage, patients have experienced primarily gastrointestinal symptoms including stomach and abdominal pain, vomiting, and diarrhea.Or drowsiness have also been observed in a small number of patients.In the case of overdosage, discontinue amoxicillin and clavulanate potassium, treat symptomatically, and institute supportive measures as required.The overdosage is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed.Prospective study of 51 pediatric patients at a poison center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying.Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin.In some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients.Of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.Renal impairment appears to be reversible with cessation of drug administration.Blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of both amoxicillin and clavulanate.Amoxicillin and clavulanate are removed from the circulation by hemodialysis.

See more: amoxicillin 500 mg

Acomplia: Remedy What is Acomplia? Acomplia (rimonabant) is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1). Acomplia is used in the treatment of obesity and related conditions. How does Acomplia work? Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle1. Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis. CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised physiological system that includes receptors such as the CB1 receptor and it has been shown to play an important role in regulating body weight and in controlling energy balance, as well as glucose and lipid (or fat) metabolism. What is Acomplia used for? Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood. Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease. Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug. Does Acomplia also aid smoking cessation? Acomplia has been studied by sanofi-aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking. Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia for use in smoking cessation. An approvable letter was however issued for Acomplia for use in weight management. Acomplia has just been approved in the European Union. Is Acomplia approved in the United States? No. Sanofi is still awaiting U.S. marketing go-ahead which it has said could come by the end of this year. U.S. health authorities have asked Sanofi for more information on Acomplia. Acomplia received European Union marketing approval in June 2006. The first launch will take place in Britain in July and be followed by launches in Denmark, Ireland, Germany, Finland and Norway in the second half of this year, according to Sanofi. What were the results of Acomplia Clinical trial studies? In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss4,5. Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia 20mg was beyond that expected from weight loss alone6. What are the side-effects of Acomplia? Side effects in the trial on Acomplia in obesity were vomiting and nausea, forcing about 19 percent of patients to leave the trial versus 13 percent of those who took placebo.

More info about amoxicillin 500 mg

Good news: My boyfriend Josh Duhamel is now doing Gap ads. Check him out on Gap.com. Drool.
Weird news: Just got a text message from SpeedDating Guy. It reads, How are you? What. The. Hell.
And in more weird news: Remember the comic-turned-chiropractor that was given my phone number by a coworker? He called. We talked for a bit and he seems totally cool. Buts only 5 (Im 5) and as horrible as this sounds, I have height issues. I think we may get together for coffee sometime soon.

More info about amoxicillin 500 mg

Good news: My boyfriend Josh Duhamel is now doing Gap ads. Check him out on Gap.com. Drool.
Weird news: Just got a text message from SpeedDating Guy. It reads, How are you? What. The. Hell.
And in more weird news: Remember the comic-turned-chiropractor that was given my phone number by a coworker? He called. We talked for a bit and he seems totally cool. Buts only 5 (Im 5) and as horrible as this sounds, I have height issues. I think we may get together for coffee sometime soon.

See more: amoxicillin 500 mg

See more: amoxicillin 500 mg

Is an analog of ampicillin, derived from the basic penicillin nucleus, 6- aminopenicillanic acid.Amoxicillin molecular formula is C 16H19N3O5S3H2O, and the molecular weight is 419.Chemically, amoxicillin is (2S,5R,6R)-6-heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus.Is a ОІ-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of ОІ-lactamases by blocking the active sites of these enzymes.Is particularly active against the clinically important plasmid-mediated ОІ-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins.Clavulanate potassium molecular formula is C8H8KNO5, and the molecular weight is 237.Chemically, clavulanate potassium is potassium (Z 2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4- oxa-1-azabicyclo-heptane-2-carboxylate and may be represented structurally as: Powder for Oral Suspension:Each 5 mL of reconstituted amoxicillin and clavulanate potassium for oral suspension 200 mg/5 mL contains 0.Potassium.5 mL of reconstituted amoxicillin and clavulanate potassium for oral suspension 400 mg/5 mL contains 0.Inactive Ingredients: Aspartame, colloidal silicon dioxide, flavor strawberry, flavor strawberry guarana, monosodium citrate, silicon dioxide, sodium citrate (as dihydrate), xanthan gum.Chewable Tablets:Each 200 mg/28.Chewable tablet contains 0.Each 400 mg chewable tablet contains 0.Of potassium.Aspartame, FD clavulanic acid has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound.Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid.Results of experiments involving the administration of clavulanic acid to animals suggest that thispound, like amoxicillin, is well distributed in body tissues.Two hours after oral administration of a single 35 mg/kg dose of amoxicillin and clavulanate potassium suspension to fasting children, average concentrations of 3 mcg/mL of amoxicillin and 0.Of clavulanic acid were detected in middle ear effusions.Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms.Is, however, susceptible to degradation by ОІ-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes.Acid is a ОІ-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range of ОІ-lactamase enzymesmonly found in microorganisms resistant to penicillins and cephalosporins.It has good activity against the clinically important plasmid-mediated ОІ-lactamases frequently responsible for transferred drug resistance.The formulation of amoxicillin and clavulanic acid in amoxicillin and clavulanate potassium protects amoxicillin from degradation by ОІ-lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other ОІ-lactam antibiotics.Amoxicillin and clavulanate potassium possess the distinctive properties of a broad-spectrum antibiotic and a ОІ-lactamase inhibitor.Amoxicillin/clavulanic acid has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE.Gram-Positive Aerobes: Staphylococcus aureus(ОІ-lactamase and non-ОІ-lactamase-producing) Staphylococci which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid.Gram-Negative Aerobes: Enterobacterspecies (Although most strains of Enterobacter species are resistant in vitro, clinical efficacy has been demonstrated with amoxicillin and clavulanate potassium in urinary tract infections caused by these organisms.Escherichia coli(ОІ-lactamase and non-ОІ-lactamase-producing) Haemophilus influenzae(ОІ-lactamase and non-ОІ-lactamase-producing) Klebsiellaspecies (All known strains are ОІ-lactamase-producing.Moraxella catarrhalis(ОІ-lactamase and non-ОІ-lactamase-producing) The following in vitro data are available, but their clinical significance is unknown.Amoxicillin/clavulanic acid exhibits in vitro minimal inhibitory concentrations (MICs) of 0.Or less against most ( 90%) strains of Streptococcus pneumoniaeв MICs of 0.Or less against most ( 90%) strains of Neisseria gonorrhoeae; MICs of 4 mcg/mL or less against most ( 90%) strains of staphylococci and anaerobic bacteria; and MICs of 8 mcg/mL or less against most ( 90%) strains of other listed organisms.The exception of organisms shown to respond to amoxicillin alone, the safety and effectiveness of amoxicillin /clavulanic acid in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.Amoxicillin has greater in vitro activity against S.Ampicillin or penicillin, the majority of S.With intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin.Gram-Positive Aerobes: Enterococcus faecalis Staphylococcus epidermidis (ОІ-lactamase and non-ОІ-lactamase-producing) Staphylococcus saprophyticus (ОІ-lactamase and non-ОІ-lactamase-producing) Streptococcus pneumoniae Streptococcus pyogenes viridans group Streptococcus Gram-Negative Aerobes: Eikenella corrodens(ОІ-lactamase and non-ОІ-lactamase-producing) Neisseria gonorrhoeae(ОІ-lactamase and non-ОІ-lactamase-producing) Proteus mirabilis(ОІ-lactamase and non-ОІ-lactamase-producing) Anaerobic Bacteria: Bacteroidesspecies, including Bacteroides fragilis (ОІ-lactamase and non-ОІ-lactamase-producing) Fusobacteriumspecies (ОІ-lactamase and non-ОІ-lactamase-producing) Peptostreptococcusspecies Adequate and well-controlled clinical trials have established the effectiveness of amoxicillin alone in treating certain clinical infections due to these organisms.These are non-ОІ-producing organisms, and therefore, are susceptible to amoxicillin alone.Susceptibility Testing:Dilution Techniques: Quantitative methods are used to determine antimicrobial MICs.Provide estimates of the susceptibility of bacteria to antimicrobialpounds.MICs should be determined using a standardized procedure.Procedures are based on a dilution method 1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of amoxicillin/clavulanate potassium powder.The rmended dilution pattern utilizes a constant amoxicillin/clavulanate potassium ratio of 2 to 1 in all tubes with varying amounts of amoxicillin.Are expressed in terms of the amoxicillin concentration in the presence of clavulanic acid at a constant 2 parts amoxicillin to1 part clavulanic acid.Values should be interpreted according to the following criteria: RMENDED RANGES FOR AMOXICILLIN /CLAVULANIC ACID SUSCEPTIBILITY TESTING For Gram-Negative Enteric Aerobes: MIC (mcg/mL) Interpretation 8/4 Susceptible (S) 16/8 Intermediate (I) 32/16 Resistant (R) For Staphylococcus and Haemophilus species: MIC (mcg/mL) Interpretation 4/2 Susceptible (S) 8/4 Resistant (R) Staphylococci which are susceptible to amoxicillin/clavulanic acid but resistant to methicillin/oxacillin must be considered as resistant.For S.From non-meningitis sources:Isolates should be tested using amoxicillin/clavulanic acid and the following criteria should be used: MIC (mcg/mL) Interpretation 2/1 Susceptible (S) 4/2 Intermediate (I) 8/4 Resistant (R) Note: These interpretive criteria are based on the rmended doses for respiratory tract infections.A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobialpound in the blood reaches the concentration usually achievable.Report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.Category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.Category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation.Report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobialpound in the blood reaches the concentrations usually achievable; other therapy should be selected.Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.Amoxicillin /clavulanate potassium powder should provide the following MIC values: Microorganism MIC Range (mcg/mL) E.ATCC 25922 2 to 8 E.ATCC 35218 4 to 16 E.ATCC 29212 0.1 H.ATCC 49247 2 to 16 S.ATCC 29213 0. S.ATCC 49619 0.0.Expressed as concentration of amoxicillin in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid.Diffusion Techniques:Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobialpounds.Such standardized procedure 2 requires the use of standardized inoculum concentrations.Uses paper disks impregnated with 30 mcg of amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) to test the susceptibility of microorganisms to amoxicillin/clavulanic acid.Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) disk should be interpreted according to the following criteria: RMENDED RANGES FOR AMOXICILLIN/CLAVULANIC ACID SUSCEPTIBILITY TESTING For Staphylococcus species and H.Zone Diameter (mm) Interpretation 20 Susceptible (S) 19 Resistant (R) For Other Organisms Except S.And N.Zone Diameter (mm) Interpretation 18 Susceptible (S) 14 to 17 Intermediate (I) 13 Resistant (R) Staphylococci which are resistant to methicillin/oxacillin must be considered as resistant to amoxicillin/clavulanic acid.AA broth microdilution method should be used for testing H.Beta-lactamase-negative, ampicillin-resistant strains must be considered resistant to amoxicillin/clavulanic acid.Of S.Should be determined using a 1 mcg oxacillin disk.With oxacillin zone sizes of 20 mm are susceptible to amoxicillin/clavulanic acid.Amoxicillin/clavulanic acid MIC should be determined on isolates of S.With oxacillin zone sizes of 19 mm.CA broth microdilution method should be used for testing N.Interpreted according to penicillin breakpoints.Interpretation should be as stated above for results using dilution techniques.Involves correlation of the diameter obtained in the disk test with the MIC for amoxicillin/clavulanic acid.As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures.The diffusion technique, the 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) disk should provide the following zone diameters in these laboratory quality control strains: Microorganism Zone Diameter (mm) E.ATCC 25922 19 to 25 mm E.ATCC 35218 18 to 22 mm S.ATCC 25923 28 to 36 mm INDICATIONS AND USAGE Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections- caused by ОІ-lactamase-producing strains of H.And M. Otitis Media- caused by ОІ-lactamase-producing strains of H.M. Sinusitis- caused by ОІ-lactamase-producing strains of H.M. Skin and Skin Structure Infections- caused by ОІ-lactamase-producing strains of S.E.And Klebsiella spp.Urinary Tract Infections- caused by ОІ-lactamase-producing strains of E.Spp.Enterobacter spp.While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content.Infections caused by ampicillin-susceptible organisms and ОІ-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic.Amoxicillin has greater in vitro activity against S.Than does ampicillin or penicillin, the majority of S.With intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium.Microbiology.To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.And susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.The absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures.Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) are contraindicated in patients with a history of allergic reactions to any penicillin.Is also contraindicated in patients with a previous history of amoxicillin and clavulanate potassium associated cholestatic jaundice/hepatic dysfunction.WARNINGS SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY.REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS.HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS.INITIATING THERAPY WITH AMOXICILLIN AND CLAVULANATE POTASSIUM, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS.AN ALLERGIC REACTION OCCURS AMOXICILLIN AND CLAVULANATE POTASSIUM SHOULD BE DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED.ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE.INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.Clostridium difficileassociated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin and clavulanate potassium, and may range in severity from mild diarrhea to fatal colitis.With antibacterial agents alters the normal flora of the colon leading to overgrowth of C. C.Toxins A and B which contribute to the development of CDAD.Producing strains of C.Increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.Be considered in all patients who present with diarrhea following antibiotic use.Medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C.May need to be discontinued.Fluid and electrolyte management, protein supplementation, antibiotic treatment of C.And surgical evaluation should be instituted as clinically indicated.Amoxicillin and clavulanate potassium should be used with caution in patients with evidence of hepatic dysfunction.Toxicity associated with the use of amoxicillin and clavulanate potassium is usually reversible.Occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide).Have generally been cases associated with serious underlying diseases or coitant medications.CONTRAINDICATIONS and ADVERSE REACTIONS †Liver.General:While amoxicillin and clavulanate potassium possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable during prolonged therapy.A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous skin rash.Antibiotics should not be administered to patients with mononucleosis.Of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy.Occur (usually involving Pseudomonas or Candida), the drug should be discontinued and/or appropriate therapy instituted.Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.FOR THE PATIENT Amoxicillin and clavulanate potassium may be taken every 8 hours or every 12 hours, depending on the strength of the product prescribed.Should be taken with a meal or snack to reduce the possibility of gastrointestinal upset.Antibiotics can cause diarrhea.Diarrhea is severe or lasts more than 2 or 3 days, call your doctor.Diarrhea is amon problem caused by antibiotics which usually ends when the antibiotic is discontinued.After starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic.This occurs, patients should contact their physician as soon as possible.Keep suspension refrigerated.Well before using.Dosing a child with amoxicillin and clavulanate potassium for oral suspension (liquid), use a dosing spoon or medicine dropper.Sure to rinse the spoon or dropper after each use.Amoxicillin and clavulanate potassium for oral suspension may contain more liquid than required.Your doctor's instructions about the amount to use and the days of treatment your child requires.Any unused medicine.Patients should be counseled that antibacterial drugs including amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should only be used to treat bacterial infections.Do not treat viral infections (e.Themon cold).And clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is prescribed to treat a bacterial infection, patients should be told that although it ismon to feel better early in the course of therapy, the medication should be taken exactly as directed.Doses or notpleting the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) or other antibacterial drugs in the future.Phenylketonurics Each 200 mg amoxicillin and clavulanate potassium chewable tablet contains 3.Phenylalanine; each 400 mg chewable tablet contains 7 mg phenylalanine; each 5 mL of either the 200 mg/5 mL or 400 mg/5 mL oral suspension contains 7 mg phenylalanine.Other products of amoxicillin and clavulanate potassium do not contain phenylalanine and can be used by phenylketonurics.Your physician or pharmacist.DRUG INTERACTIONS Probenecid decreases the renal tubular secretion of amoxicillin.With amoxicillin and clavulanate potassium may result in increased and prolonged blood levels of amoxicillin.Probenecid cannot be rmended.The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs aspared to patients receiving ampicillin alone.Not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.Are no data with amoxicillin and clavulanate potassium and allopurinol administered concurrently.Inmon with other broad-spectrum antibiotics, amoxicillin and clavulanate potassium may reduce the efficacy of oral contraceptives.DRUG/LABORATORY TEST INTERACTIONS Oral administration of amoxicillin and clavulanate potassium will result in high urine concentrations of amoxicillin.Urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST (R), Benedict's Solution, or Fehling's Solution.This effect may also occur with amoxicillin and therefore amoxicillin and clavulanate potassium, it is rmended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX(R)) be used.Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.Effect may also occur with amoxicillin and therefore amoxicillin and clavulanate potassium.CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY Long-term studies in animals have not been performed to evaluate carcinogenic potential.Mutagenesis:The mutagenic potential of amoxicillin and clavulanate potassium was investigated in vitro with an Ames test, a human lymphocyte cytogenetic assay, a yeast test and a mouse lymphoma forward mutation assay, and in vivo with mouse micronucleus tests and a dominant lethal test.Were negative apart from the in vitro mouse lymphoma assay where weak activity was found at very high, cytotoxic concentrations.Of Fertility:Amoxicillin and clavulanate potassium at oral doses of up to 1,200 mg/kg/day (5.The maximum human dose, 1,480 mg/m 2/day, based on body surface area) was found to have no effect on fertility and reproductive performance in rats, dosed with a 2:1 ratio formulation of amoxicillin:clavulanate.Teratogenic effects:Pregnancy (Category B).Studies performed in pregnant rats and mice given amoxicillin and clavulanate potassium at oral dosages up to 1,200 mg/kg/day, equivalent to 7,200 and 4,080 mg/m 2/day, respectively (4.2.The maximum human oral dose based on body surface area), revealed no evidence of harm to the fetus due to amoxicillin and clavulanate potassium.Are, however, no adequate and well-controlled studies in pregnant women.Animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.LABOR AND DELIVERY Oral ampicillin-class antibiotics are generally poorly absorbed during labor.In guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions.Is not known whether the use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.A single study in women with premature rupture of fetal membranes, it was reported that prophylactic treatment with amoxicillin and clavulanate potassium may be associated with an increased risk of necrotizing enterocolitis in neonates.NURSING MOTHERS Ampicillin-class antibiotics are excreted in the milk; therefore, caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman.PEDIATRIC USE Because of ipletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed.Of amoxicillin and clavulanate potassium should be modified in pediatric patients younger than 12 weeks (3 months).DOSAGE AND ADMINISTRATIONвЂPediatric.ADVERSE REACTIONS Amoxicillin and clavulanate potassium is generally well tolerated.Of side effects observed in clinical trials were of a mild and transient nature and less than 3% of patients discontinued therapy because of drug-related side effects.The original premarketing studies, where both pediatric and adult patients were enrolled, the most frequently reported adverse effects were diarrhea/loose stools (9%), nausea (3%), skin rashes and urticaria (3%), vomiting (1%) and vaginitis (1%).Overall incidence of side effects, and in particular diarrhea, increased with the higher rmended dose.Less frequently reported reactions include: Abdominal difort, flatulence, and headache.In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted whichpared amoxicillin and clavulanate potassium 45/6.(divided q12h) for 10 days versus amoxicillin and clavulanate potassium 40/10 mg/kg/day (divided q8h) for 10 days in the treatment of acute otitis media.Total of 575 patients were enrolled, and only the suspension formulations were used in this trial.The adverse event profile seen wasparable to that noted above; however, there were differences in the rates of diarrhea, skin rashes/urticaria, and diaper area rashes.CLINICAL STUDIES.The following adverse reactions have been reported for ampicillin-class antibiotics: Gastrointestinal:Diarrhea, nausea, vomiting, indigestion, gastritis, stomatitis, glossitis, black "hairy" tongue, mucocutaneous candidiasis, enterocolitis, and hemorrhagic/pseudomembranous colitis.Pseudomembranous colitis symptoms may occur during or after antibiotic treatment.WARNINGS.Reactions:Skin rashes, pruritus, urticaria, angioedema, serum sickness-like reactions (urticaria or skin rash apanied by arthritis, arthralgia, myalgia, and frequently fever), erythema multiforme (rarely Stevens-Johnson syndrome), acute generalized exanthematous pustulosis, hypersensitivity vasculitis, and an occasional case of exfoliative dermatitis (including toxic epidermal necrolysis) have been reported.Reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids.Such reactions occur, the drug should be discontinued, unless the opinion of the physician dictates otherwise.Occasional fatal hypersensitivity (anaphylactic) reactions can occur with oral penicillin.WARNINGS.Liver:A moderate rise in AST (SGOT) and/or ALT (SGPT) has been noted in patients treated with ampicillin-class antibiotics, but the significance of these findings is unknown.Dysfunction, including hepatitis and cholestatic jaundice, (see CONTRAINDICATIONS), increases in serum transaminases (AST and/or ALT), serum bilirubin and/or alkaline phosphatase, has been infrequently reported with amoxicillin and clavulanate potassium.Has been reported moremonly in the elderly, in males, or in patients on prolonged treatment.Findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes.Onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued.Dysfunction, which may be severe, is usually reversible.Occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide).Have generally been cases associated with serious underlying diseases or coitant medications.Renal:Interstitial nephritis and hematuria have been reported rarely.Has also been reported (see OVERDOSAGE).And Lymphatic Systems:Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and agranulocytosis have been reported during therapy with penicillins.Reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.Slight thrombocytosis was noted in less than 1% of the patients treated with amoxicillin and clavulanate potassium.Have been reports of increased prothrombin time in patients receiving amoxicillin and clavulanate potassium and anticoagulant therapy coitantly.Central Nervous System:Agitation, anxiety, behavioral changes, confusion, convulsions, dizziness, insomnia, and reversible hyperactivity have been reported rarely.Miscellaneous:Tooth discoloration (brown, yellow, or gray staining) has been rarely reported.Reports occurred in pediatric patients.Reduced or eliminated with brushing or dental cleaning in most cases.OVERDOSAGE Following overdosage, patients have experienced primarily gastrointestinal symptoms including stomach and abdominal pain, vomiting, and diarrhea.Or drowsiness have also been observed in a small number of patients.In the case of overdosage, discontinue amoxicillin and clavulanate potassium, treat symptomatically, and institute supportive measures as required.The overdosage is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed.Prospective study of 51 pediatric patients at a poison center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying.Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin.In some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients.Of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.Renal impairment appears to be reversible with cessation of drug administration.Blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of both amoxicillin and clavulanate.Amoxicillin and clavulanate are removed from the circulation by hemodialysis.

More info about amoxicillin 500 mg